MedTrace Logo

A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors

NCT06143007 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-11-17

No results posted yet for this study

Summary

This is a Phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics, efficacy and preliminary food effect of BB3008 as monotherapy in subjects with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

BB3008 tablet

BB3008 tablets will be administered orally once daily (QD).

Sponsors & Collaborators

  • Broadenbio Ltd., Co.

    lead INDUSTRY

Principal Investigators

  • Jing Huang, MD · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-26
Primary Completion
2025-05-22
Completion
2026-04-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06143007 on ClinicalTrials.gov